Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Erythropoietic protoporphyria (EPP)(Stage not disclosed)
X-linked protoporphyria (XLP)(Stage not disclosed)
Status note Lead program. FDA accepted the NDA for review in November 2025 but issued a complete response letter (CRL) in February 2026; resubmission path not dated in the filing. HELIOS open-label long-term extension study ongoing in EPP/XLP patients. Awarded FDA Commissioner's National Priority Voucher (CNPV) for bitopertin in EPP/XLP in October 2025.
DISC-0974
Phase 2 · ActiveModality: monoclonal antibody
Aliases selcodebart
Target hemojuvelin (HJV)
Partnerships Licensed from AbbVie Deutschland GmbH & Co ($5.0M milestone triggered in Q1 2026)
Indications
Anemia of myelofibrosis (MF)(Phase 2)
Catalysts
— second half of 2026
Status note Lead product candidate of the iron homeostasis portfolio; hepcidin-suppressing anti-HJV antibody. Evaluated in RALLY-MF, an open-label Phase 2 trial in anemia of MF. Company also plans to explore other indications.
DISC-3405
Phase 2 · ActiveModality: monoclonal antibody
Target TMPRSS6
Partnerships Licensed from Mabwell Therapeutics, Inc ($5.0M Phase 1 milestone paid Q1 2026; $10.0M due on first Phase 2 administration)
Indications
Polycythemia vera (PV)(Phase 2)
Sickle cell disease (SCD)(Phase 1)
Other hematologic disorders(Stage not disclosed)
Catalysts
— third quarter of 2026
— fourth quarter of 2026
Status note Anti-TMPRSS6 antibody for therapeutic iron restriction. RESTORE-PV open-label Phase 2 in PV initiated June 2025; Phase 1b open-label trial in SCD initiated October 2025. Company plans to explore other hematologic disorders.
DISC-0998
Preclinical · ActiveModality: monoclonal antibody
Target hemojuvelin (HJV)
Partnerships Licensed from AbbVie
Status note Preclinical next-generation anti-HJV monoclonal antibody designed to increase serum iron levels with extended serum half-life vs DISC-0974.
Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.